About Pathalys
Pathalys is a company based in Raleigh (United States) founded in 2021.. Pathalys has raised $105 million across 2 funding rounds from investors including J P Morgan, The Carlyle Group and Marshall Wace. Pathalys offers products and services including Upacicalcet. Pathalys operates in a competitive market with competitors including Evergreen Nephrology, AdaptX, Bial, Specialty Networks and Ceresti, among others.
- Headquarter Raleigh, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Pathalys Pharma, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$105 M (USD)
in 2 rounds
-
Latest Funding Round
$105 M (USD), Series B
Aug 20, 2024
-
Investors
J P Morgan
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Pathalys
Pathalys offers a comprehensive portfolio of products and services, including Upacicalcet. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats secondary hyperparathyroidism in kidney disease patients.
Funding Insights of Pathalys
Pathalys has successfully raised a total of $105M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $105 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $105.0M
- First Round First Round
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2024 | Amount | Series B - Pathalys | Valuation | TCG Crossover | |
| Jan, 2023 | Amount | Seed - Pathalys | Valuation | Abingworth |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Pathalys
Pathalys has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include J P Morgan, The Carlyle Group and Marshall Wace. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Founded Year | Domain | Location | |
|
Long-short equity strategies are managed through specialized hedge funds.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Pathalys
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Pathalys
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pathalys Comparisons
Competitors of Pathalys
Pathalys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evergreen Nephrology, AdaptX, Bial, Specialty Networks and Ceresti, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Chronic care management services for kidney diseases are provided.
|
|
| domain | founded_year | HQ Location |
Clinical management solutions are provided for healthcare by AdaptX.
|
|
| domain | founded_year | HQ Location |
Develops and commercializes pharmaceutical products through research and global distribution.
|
|
| domain | founded_year | HQ Location |
Specialty Networks is focused on supporting independent specialty healthcare providers.
|
|
| domain | founded_year | HQ Location |
Provider of chronic care management and monitoring solutions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pathalys
Frequently Asked Questions about Pathalys
When was Pathalys founded?
Pathalys was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Where is Pathalys located?
Pathalys is headquartered in Raleigh, United States. It is registered at Raleigh, North Carolina, United States.
Who is the current CEO of Pathalys?
Neal Fowler is the current CEO of Pathalys.
Is Pathalys a funded company?
Pathalys is a funded company, having raised a total of $105M across 2 funding rounds to date.
What does Pathalys do?
Pathalys was founded in 2021 and is based in Raleigh, United States. Development services for biotherapeutics targeting chronic kidney disease are provided within the biotechnology sector. Operations center on advancing therapeutic solutions for CKD patients. The company is led by CEO Neal Fowler, with a focus on research and innovation in renal health treatments.
Who are the top competitors of Pathalys?
Pathalys's top competitors include Evergreen Nephrology, Aqtual and AdaptX.
What products or services does Pathalys offer?
Pathalys offers Upacicalcet.
Who are Pathalys's investors?
Pathalys has 11 investors. Key investors include J P Morgan, The Carlyle Group, Marshall Wace, Orbimed, and Abingworth.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.